TWOEquity · Weekly research terminal

6615

Sofiva Genomics Co.,Ltd.

TW Healthcare Diagnostics & Research

Latest week
14 Aug 2026
Weekly close
33.75 TWD
Fair value
39.72 TWD
Next-week expectancy
Negative 44.68%
Sharemaestro
Weekly Chart Pack Completed weekly market data · Independent research

TWO · Equity · Taiwan

6615

Sofiva Genomics Co.,Ltd.

Healthcare Diagnostics & Research

Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessment for early/late-onset preeclampsia, folate metabolism genetic testing, …

Last updated
14 Aug 2026
Exchange
Taipei Exchange · TWO
Sector
Healthcare
Industry
Diagnostics & Research
Currency
TWD
Market capitalisation
728,777,280
Fair value reference
39.72
Next-week expectancy
Negative · 44.68%

Over the latest 12 completed weeks ending 2026-08-14, 6615 rose 2.74%, moving from 32.85 to 33.75. The latest weekly close is below the Trend Line and below Fair Value. Trend Signal is active on the latest week and was active in 12 of the last 12 weeks. Relative Strength is -26.37 and has improved across the 12-week window. Market Dynamics is -0.30 on the latest week. Next-week expectancy is negative at 44.68% based on similar historical setup states.

Week Ending
14 Aug 2026
Latest Close
33.75
12-Week Change
2.74%
Trend Signal
Active
Next-Week Expectancy
Negative 44.68%
Signal Weeks
12 of 12

Weekly Price

Weekly Close Trend Line Fair Value Activity Lines

Chart Panels

Choose up to 5 panels. Drag panel headers to reorder.

Chart Summary

Key Points

Week Ending
14 Aug 2026
Latest Close
33.75
12-Week Change
2.74%
Trend Signal
Active
Next-Week Expectancy
Negative 44.68%
Signal Weeks
12 of 12
Vs Trend Line
Below
Vs Fair Value
Below
Relative Strength
-26.37
Market Dynamics
-0.30

Over the latest 12 completed weeks ending 2026-08-14, 6615 rose 2.74%, moving from 32.85 to 33.75. The latest weekly close is below the Trend Line and below Fair Value. Trend Signal is active on the latest week and was active in 12 of the last 12 weeks. Relative Strength is -26.37 and has improved across the 12-week window. Market Dynamics is -0.30 on the latest week. Next-week expectancy is negative at 44.68% based on similar historical setup states.

Industry Peers

Taiwan equities in Diagnostics & Research

Stock Exchange Week Open High Low Close Change
6847 Puriblood Medical Co., Ltd. TWO 14 Aug 2026 77.70 81.40 75.80 79.30 2.06%
6939 TFBS Bioscience Inc. TWO 14 Aug 2026 19.50 20.00 18.70 19.65 0.77%
7595 Pharmigene, Inc. TWO 14 Aug 2026 7.20 7.36 6.90 7.25 0.69%
1784 BIONET Corp. TWO 14 Aug 2026 60.20 62.90 60.20 60.60 0.66%
4160 Genetics Generation Advancement Corp. TWO 14 Aug 2026 40.15 41.00 39.40 39.80 -0.87%
4153 DIVA Laboratories, Ltd. TWO 14 Aug 2026 33.45 33.45 32.40 33.00 -1.35%
6645 Kim Forest Enterprise Co., Ltd. TAI 14 Aug 2026 13.55 13.60 13.10 13.25 -2.21%
6661 Welgene Biotech Co.,Ltd. TWO 14 Aug 2026 17.60 17.60 16.00 16.75 -4.83%

Next-week expectancy

Next-week expectancy is a short-term historical read. It compares the latest completed-week setup with broadly similar past setups and asks whether the following week tended to close higher or lower.

It is not a trend call, a price target, or a guarantee. A positive read can appear while price is below trend or activity pressure is weak, because it is measuring short-term follow-through odds for the current setup state.

Use it as one context layer beside Trend Line, Relative Strength, Market Dynamics, Fair Value, and the visible price structure.

Evidence context